Cargando…

Anti-angiogenic agents in the treatment of non-small cell lung cancer

Lung cancer is the most common malignant neoplasm diagnosed worldwide. In Poland, in 2011, lung cancer was diagnosed in 14,522 men and 6,283 women. Morbidity and mortality are nearly equal, and lung cancer is still the most common cause of cancer-related death among men as well as among women. Appro...

Descripción completa

Detalles Bibliográficos
Autores principales: Szyszka-Barth, Katarzyna, Ramlau, Katarzyna, Stencel, Dariusz, Ramlau, Rodryg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283868/
https://www.ncbi.nlm.nih.gov/pubmed/26336412
http://dx.doi.org/10.5114/kitp.2014.43841
_version_ 1782351328986529792
author Szyszka-Barth, Katarzyna
Ramlau, Katarzyna
Stencel, Dariusz
Ramlau, Rodryg
author_facet Szyszka-Barth, Katarzyna
Ramlau, Katarzyna
Stencel, Dariusz
Ramlau, Rodryg
author_sort Szyszka-Barth, Katarzyna
collection PubMed
description Lung cancer is the most common malignant neoplasm diagnosed worldwide. In Poland, in 2011, lung cancer was diagnosed in 14,522 men and 6,283 women. Morbidity and mortality are nearly equal, and lung cancer is still the most common cause of cancer-related death among men as well as among women. Approximately 80% of lung cancer cases are non-small-cell lung cancer. The most commonly applied chemotherapy regimens do not produce satisfactory effects. Oncological research is now focused on molecular targeted therapies; immunotherapy is also under evaluation. The formation of abnormal blood vessels has an enormous impact on the development and progression of a tumor. Bevacizumab is a monoclonal antibody which binds VEGF (vascular endothelial growth factor). A different group of drugs is constituted by small-molecule antiangiogenic tyrosine kinase inhibitors. These agents represent a different profile of side effects in comparison to chemotherapy. The mode of action, differing from cytotoxic drugs, requires renewed analysis as well as standardization of radiological response assessment criteria.
format Online
Article
Text
id pubmed-4283868
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-42838682015-09-02 Anti-angiogenic agents in the treatment of non-small cell lung cancer Szyszka-Barth, Katarzyna Ramlau, Katarzyna Stencel, Dariusz Ramlau, Rodryg Kardiochir Torakochirurgia Pol Thoracic Surgery Lung cancer is the most common malignant neoplasm diagnosed worldwide. In Poland, in 2011, lung cancer was diagnosed in 14,522 men and 6,283 women. Morbidity and mortality are nearly equal, and lung cancer is still the most common cause of cancer-related death among men as well as among women. Approximately 80% of lung cancer cases are non-small-cell lung cancer. The most commonly applied chemotherapy regimens do not produce satisfactory effects. Oncological research is now focused on molecular targeted therapies; immunotherapy is also under evaluation. The formation of abnormal blood vessels has an enormous impact on the development and progression of a tumor. Bevacizumab is a monoclonal antibody which binds VEGF (vascular endothelial growth factor). A different group of drugs is constituted by small-molecule antiangiogenic tyrosine kinase inhibitors. These agents represent a different profile of side effects in comparison to chemotherapy. The mode of action, differing from cytotoxic drugs, requires renewed analysis as well as standardization of radiological response assessment criteria. Termedia Publishing House 2014-06-29 2014-06 /pmc/articles/PMC4283868/ /pubmed/26336412 http://dx.doi.org/10.5114/kitp.2014.43841 Text en Copyright © 2014 http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Thoracic Surgery
Szyszka-Barth, Katarzyna
Ramlau, Katarzyna
Stencel, Dariusz
Ramlau, Rodryg
Anti-angiogenic agents in the treatment of non-small cell lung cancer
title Anti-angiogenic agents in the treatment of non-small cell lung cancer
title_full Anti-angiogenic agents in the treatment of non-small cell lung cancer
title_fullStr Anti-angiogenic agents in the treatment of non-small cell lung cancer
title_full_unstemmed Anti-angiogenic agents in the treatment of non-small cell lung cancer
title_short Anti-angiogenic agents in the treatment of non-small cell lung cancer
title_sort anti-angiogenic agents in the treatment of non-small cell lung cancer
topic Thoracic Surgery
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283868/
https://www.ncbi.nlm.nih.gov/pubmed/26336412
http://dx.doi.org/10.5114/kitp.2014.43841
work_keys_str_mv AT szyszkabarthkatarzyna antiangiogenicagentsinthetreatmentofnonsmallcelllungcancer
AT ramlaukatarzyna antiangiogenicagentsinthetreatmentofnonsmallcelllungcancer
AT stenceldariusz antiangiogenicagentsinthetreatmentofnonsmallcelllungcancer
AT ramlaurodryg antiangiogenicagentsinthetreatmentofnonsmallcelllungcancer